SFI
VERV

Susquehanna Fundamental Investments’s Verve Therapeutics VERV Stock Holding History

Susquehanna Fundamental Investments’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-80,000
Closed -$898K – 770
2025
Q2 		$898K Sell
80,000
-204,237
-72% -$1.16M 0.02% 463
2025
Q1 		$1.3M Sell
284,237
-7,146
-2% -$47.9K 0.02% 631
2024
Q4 		$1.64M Buy
+291,383
New +$1.64M 0.02% 583
2024
Q2 		$649K Buy
132,998
+118,628
+826% +$746K 0.02% 637
2024
Q1 		$191K Buy
+14,370
New +$191K 0.01% 626

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Susquehanna Fundamental Investments's VERV Position: Q3 2025 in Review

Susquehanna Fundamental Investments sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 80,000 shares — an estimated $898K sold.

Susquehanna Fundamental Investments first reported a position in VERV in Q1 2024 and held it in 5 quarters. The position peaked at $1.64M in Q4 2024. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Susquehanna Fundamental Investments reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 80,000 Verve Therapeutics shares in Q3 2025, an estimated $898K.
  • Susquehanna Fundamental Investments first reported a position in Verve Therapeutics in Q1 2024 and held it in 5 quarters.
  • Susquehanna Fundamental Investments's Verve Therapeutics position peaked at $1.64M in Q4 2024.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q3 2025, filed 14 Nov 2025.